Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

ONAPGO (apomorphine hydrochloride) launched in the U.S. in April 2025. ... Supernus will host a conference call and webcast today, May 6, 2025, at 4:30 p.m. Eastern Time to discuss these results.

Combined with its three other growth products (Qelbree ®, ONAPGO TM, and GOCOVRI ®), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS ...

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to acquire Sage Therapeutics, Inc. (SAGE) for up to $795 ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...